What is the normal tissues morbidity following Helical Intensity Modulated Radiation Treatment for XXXX ?

@entity5 @entity1 @entity137 @entity343
BACKGROUND AND PURPOSE: To report on normal tissues morbidity following IMRT for @entity5 . MATERIAL AND METHODS: The first 61 @entity1 of a prospective series were included. 50Gy to the @entity343 1(pelvis) and 60Gy to the @entity343 2 (centro-pelvic disease and GTV nodes) were delivered concomitantly in 28 fractions, followed by a brachytherapy boost. For the small bowel, 50Gy was the maximal dose, while V45 and V40 had to be <50cc and 200cc, respectively. For the bladder, rectum and sigmoid structures, 60Gy was the maximal dose, and V45 and V40 had to be <20% and <50%. Acute and late @entity137 data were prospectively collected. RESULTS: The median follow-up period was 40months (range: 23-60). 30% and 90% of acute and moderate late side effects were reported respectively. Considering the AUC data of the organs at risk (OAR) DVH, late morbidity and doses were significantly linked (p   0.03), predominantly between 10Gy and 40Gy, considering the small bowel and sigmoid colon. The high dose regions exhibited no significant impact. CONCLUSION: The moderate dose volumes represent the predominant cause of morbidity after IMRT. Prospective trials are thus required to investigate new ways of dose distribution within the OAR.
